235 related articles for article (PubMed ID: 21952556)
21. Thalidomide for the treatment of chronic refractory prurigo nodularis.
Aguh C; Kwatra SG; He A; Okoye GA
Dermatol Online J; 2018 Mar; 24(3):. PubMed ID: 29634881
[TBL] [Abstract][Full Text] [Related]
22. Development of polyneuropathy during thalidomide therapy.
Wulff CH; Høyer H; Asboe-Hansen G; Brodthagen H
Br J Dermatol; 1985 Apr; 112(4):475-80. PubMed ID: 2986670
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide neuropathy: an electrophysiologic study.
Lagueny A; Rommel A; Vignolly B; Taieb A; Vendeaud-Busquet M; Doutre MS; Julien J
Muscle Nerve; 1986; 9(9):837-44. PubMed ID: 3023998
[TBL] [Abstract][Full Text] [Related]
24. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.
Lan CC; Lin CL; Wu CS; Chai CY; Chen WT; Chen GS
J Dermatol; 2007 Apr; 34(4):237-42. PubMed ID: 17352720
[TBL] [Abstract][Full Text] [Related]
25. Treatment of prurigo nodularis with thalidomide.
van den Broek H
Arch Dermatol; 1980 May; 116(5):571-2. PubMed ID: 7377791
[TBL] [Abstract][Full Text] [Related]
26. Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo.
Estrada-G I; Garibay-Escobar A; Núñez-Vázquez A; Hojyo-Tomoka T; Vega-Memije E; Cortés-Franco R; Pérez-Uribe A; Flores-Romo L; Santos-Argumedo L; Estrada-Parra S; Domínguez-Soto L
Int J Dermatol; 2004 Dec; 43(12):893-7. PubMed ID: 15569010
[TBL] [Abstract][Full Text] [Related]
27. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients.
Coelho A; Souto MI; Cardoso CR; Salgado DR; Schmal TR; Waddington Cruz M; de Souza Papi JA
Lupus; 2005; 14(6):434-9. PubMed ID: 16038106
[TBL] [Abstract][Full Text] [Related]
28. Childhood thalidomide neuropathy: a clinical and neurophysiologic study.
Priolo T; Lamba LD; Giribaldi G; De Negri E; Grosso P; De Grandis E; Veneselli E; Buoncompagni A; Viola S; Alpigiani MG; Gandullia P; Calevo MG
Pediatr Neurol; 2008 Mar; 38(3):196-9. PubMed ID: 18279755
[TBL] [Abstract][Full Text] [Related]
29. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
[TBL] [Abstract][Full Text] [Related]
30. Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome.
Zhang L; Au S; Aronson IK
Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526013
[TBL] [Abstract][Full Text] [Related]
31. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
Briani C; Zara G; Rondinone R; Iaccarino L; Ruggero S; Toffanin E; Ermani M; Ghirardello A; Zampieri S; Sarzi-Puttini P; Doria A
Autoimmunity; 2005 Nov; 38(7):549-55. PubMed ID: 16373260
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures.
Aronson IK; Yu R; West DP; Van den Broek H; Antel J
Arch Dermatol; 1984 Nov; 120(11):1466-70. PubMed ID: 6093713
[TBL] [Abstract][Full Text] [Related]
33. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
34. Thalidomide neurotoxicity.
Clemmensen OJ; Olsen PZ; Andersen KE
Arch Dermatol; 1984 Mar; 120(3):338-41. PubMed ID: 6703734
[TBL] [Abstract][Full Text] [Related]
35. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
[TBL] [Abstract][Full Text] [Related]
36. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
37. Thalidomide neuropathy: role of F-wave monitoring.
Rao DG; Kane NM; Oware A
Muscle Nerve; 2000 Aug; 23(8):1301-2. PubMed ID: 10918274
[No Abstract] [Full Text] [Related]
38. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
39. An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.
Sardana K; Gupta A; Sinha S
Clin Exp Dermatol; 2020 Jan; 45(1):92-96. PubMed ID: 31132160
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
